SCHEMBL6158718

SCHEMBL6158718

CC(=O)S[C@@H]1CC(=O)N(Cc2ccc(Oc3ccc(Cl)cc3)cc2)C1

nearest known ligand 0.52

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 3/20 0.49
S1PR5 Q9H228 1/20 0.48
SMN1; SMN2 Q16637 2/20 0.43
CYP3A4 P08684 1/20 0.41
CYP2C19 P33261 1/20 0.41
ALDH1A1 P00352 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
EGLN1 Q9GZT9 1/20 0.40
HTT P42858 1/20 0.40
MMP2 P08253 2/20 0.39
MMP1 P03956 1/20 0.39
MMP3 P08254 1/20 0.39
MMP9 P14780 1/20 0.39
MMP13 P45452 1/20 0.39
NPC1 O15118 1/20 0.38
RAB9A P51151 1/20 0.38
PKM P14618 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6158676 1.00 KMT2A (0.49) KMT2AS1PR5SMN1; SMN2CYP3A4CYP2C19
SCHEMBL6161259 0.91 SMN1; SMN2 (0.54) KMT2ASMN1; SMN2CYP3A4CYP2C19ALDH1A1
SCHEMBL6162824 0.91 ALDH1A1 (0.43) KMT2ASMN1; SMN2CYP3A4CYP2C19ALDH1A1
SCHEMBL6160166 0.91 ALDH1A1 (0.50) KMT2ASMN1; SMN2CYP3A4CYP2C19ALDH1A1
SCHEMBL6160144 0.91 SMN1; SMN2 (0.45) SMN1; SMN2CYP3A4CYP2C19ALDH1A1HTT
SCHEMBL6159695 0.91 SMN1; SMN2 (0.54) KMT2ASMN1; SMN2CYP3A4CYP2C19ALDH1A1
SCHEMBL6159136 0.91 SMN1; SMN2 (0.43) KMT2AS1PR5SMN1; SMN2CYP3A4CYP2C19
SCHEMBL6158416 0.91 SMN1; SMN2 (0.45) SMN1; SMN2CYP3A4CYP2C19ALDH1A1HTT
SCHEMBL6158423 0.91 SMN1; SMN2 (0.45) SMN1; SMN2CYP3A4CYP2C19ALDH1A1HTT
SCHEMBL6159098 0.90 HTT (0.53) KMT2AS1PR5SMN1; SMN2CYP3A4CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6953789-B2 Thiol compounds, their production and use TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 2005-10-11 US disclosed
US-20040157894-A1 Thiol compounds, their production and use TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2004-08-12 US disclosed
US-6699881-B2 MATRIX METALLOPROTEASE INHIBITORS TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 2004-03-02 US disclosed
US-20030078253-A1 Thiol compounds, their production and use TAKEDA PHARMACEUTICAL COMPANY, LIMITED (JP) 2003-04-24 US disclosed
US-6420415-B1 Thiol compounds, their production and use TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 2002-07-16 US disclosed
EP-1132379-A1 NOVEL THIOL DERIVATIVES, PROCESS FOR PRODUCING THE SAME AND UTILIZATION THEREOF Takeda Chemical Industries, Ltd. (JP) 2001-09-12 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030078253-A1 Thiol compounds, their production and use TST, QSOX1, SULT1E1 KMT2A 1898/4885S1PR5 2160/4885SMN1; SMN2 3819/4885
US-20040157894-A1 Thiol compounds, their production and use TST, SULT1E1, QSOX1 KMT2A 1850/4885S1PR5 1980/4885SMN1; SMN2 3509/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.